Skip to main content
Clinical Trials/NCT00332124
NCT00332124
Completed
Phase 1

Double-blind Trial of Phosphatidylcholine During Pregnancy and Infant Serum Choline Levels

University of Colorado, Denver1 site in 1 country351 target enrollmentJune 2006

Overview

Phase
Phase 1
Intervention
Placebo
Conditions
Pregnancy
Sponsor
University of Colorado, Denver
Enrollment
351
Locations
1
Primary Endpoint
Sensory Gaiting (P50)
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

This study will evaluate the safety and effectiveness of taking choline supplements during pregnancy, and whether choline supplementation has an effect on infant development.

Detailed Description

Choline is an essential nutrient that can be found in foods, such as egg yolks, liver, and other meats. It is important for the composition and repair of normal cellular membranes, normal brain function, and normal cardiovascular function. Research has suggested that the presence of adequate amounts of choline during pregnancy and breastfeeding can help ensure healthy fetal brain development. Additionally, adequate prenatal choline levels may have long-lasting positive effects on cognitive function, including memory. However, sufficient research has not been done on the effects of choline on pregnant women and their unborn babies. This study will evaluate the safety and effectiveness of taking choline supplements during pregnancy, and whether taking choline during pregnancy will have an effect on infant development. Participants in this double-blind study will be randomly assigned to receive either placebo or 900 mg of choline daily throughout pregnancy, until delivery. Babies will then begin receiving either placebo or choline daily from the time of birth until they are 3 months old. Participants will attend a baseline study visit that will include eligibility assessment, urine collection, measurement of vital signs, dispensing of study medication, and an ultrasound. Subsequent study visits will occur every 4 weeks throughout pregnancy and 6 months postpartum. Vital signs will be taken, urine samples will be collected, and study medication will be given at each visit. Two blood samples will be taken between Weeks 32 and 36 of gestation. Heel sticks will be performed on babies when they are 4 and 12 weeks old. Follow-up visits will be held every 6 months until the baby is 18 months old.

Registry
clinicaltrials.gov
Start Date
June 2006
End Date
March 2017
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Between 10 and 18 weeks gestational age
  • Diagnosis of psychosis

Exclusion Criteria

  • Use of any tobacco or nicotine product
  • Drinks more than 1 alcoholic drink per day
  • Use of illicit drugs
  • History of trimethylaminuria
  • History of kidney disease
  • History of liver disease
  • History of pre-pregnancy diabetes
  • History of Parkinson's disease
  • History of fetal death, fetal/infant congenital malformation, or fetal/infant genetic abnormality
  • Evidence of noncompliance to study medication

Arms & Interventions

1

Participants will take placebo

Intervention: Placebo

2

Participants will take choline

Intervention: Choline

Outcomes

Primary Outcomes

Sensory Gaiting (P50)

Time Frame: Measured at birth, 1 month and 3 months after birth

Study Sites (1)

Loading locations...

Similar Trials